Similar articles for PMID: 30413661

Year	Number of Results
1998	1
2001	1
2004	1
2007	4
2008	1
2009	1
2010	1
2011	2
2012	10
2013	8
2014	12
2015	14
2016	19
2017	30
2018	41
2019	42
2020	84
2021	84
2022	67
2023	24
2024	0

1

¹⁸F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma.

Ito K, Teng R, Schöder H, Humm JL, Ni A, Michaud L, Nakajima R, Yamashita R, Wolchok JD, Weber WA. Ito K, et al. J Nucl Med. 2019 Mar;60(3):335-341. doi: 10.2967/jnumed.118.213652. Epub 2018 Nov 9. J Nucl Med. 2019. PMID: 30413661 Free PMC article.

2

Absolute number of new lesions on ¹⁸F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab.

Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A. Anwar H, et al. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):376-383. doi: 10.1007/s00259-017-3870-6. Epub 2017 Nov 10. Eur J Nucl Med Mol Imaging. 2018. PMID: 29124281 Clinical Trial.

3

Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.

Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC. Sachpekidis C, et al. Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):386-96. doi: 10.1007/s00259-014-2944-y. Epub 2014 Oct 31. Eur J Nucl Med Mol Imaging. 2015. PMID: 25359635

4

The role of interim ¹⁸F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma.

Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289-1296. doi: 10.1007/s00259-018-3972-9. Epub 2018 Feb 24. Eur J Nucl Med Mol Imaging. 2018. PMID: 29478079 Clinical Trial.

5

Longitudinal studies of the ¹⁸F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT.

Sachpekidis C, Anwar H, Winkler JK, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Cancer Immunol Immunother. 2018 Aug;67(8):1261-1270. doi: 10.1007/s00262-018-2183-3. Epub 2018 Jun 5. Cancer Immunol Immunother. 2018. PMID: 29872898

6

Predictive value and accuracy of [¹⁸F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma.

Ayati N, Jamshidi-Araghi Z, Hoellwerth M, Schweighofer-Zwink G, Hitzl W, Koelblinger P, Pirich C, Beheshti M. Ayati N, et al. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2715-2726. doi: 10.1007/s00259-023-06247-8. Epub 2023 May 4. Eur J Nucl Med Mol Imaging. 2023. PMID: 37140669 Free PMC article.

7

Prognostic value of baseline metabolic tumor volume measured on ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy.

Ito K, Schöder H, Teng R, Humm JL, Ni A, Wolchok JD, Weber WA. Ito K, et al. Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):930-939. doi: 10.1007/s00259-018-4211-0. Epub 2018 Nov 28. Eur J Nucl Med Mol Imaging. 2019. PMID: 30488098 Free PMC article.

8

FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.

Iravani A, Osman MM, Weppler AM, Wallace R, Galligan A, Lasocki A, Hunter MO, Akhurst T, Hofman MS, Lau PKH, Kee D, Au-Yeung G, Sandhu S, Hicks RJ. Iravani A, et al. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2776-2786. doi: 10.1007/s00259-020-04815-w. Epub 2020 Apr 21. Eur J Nucl Med Mol Imaging. 2020. PMID: 32338306

9

Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using ¹⁸F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST.

Kitajima K, Watabe T, Nakajo M, Ishibashi M, Daisaki H, Soeda F, Tanemura A, Kanekura T, Yamazaki N, Ito K. Kitajima K, et al. Jpn J Radiol. 2022 Jan;40(1):75-85. doi: 10.1007/s11604-021-01174-w. Epub 2021 Jul 21. Jpn J Radiol. 2022. PMID: 34287739 Free PMC article.

10

Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors.

Annovazzi A, Vari S, Giannarelli D, Pasqualoni R, Sciuto R, Carpano S, Cognetti F, Ferraresi V. Annovazzi A, et al. Clin Nucl Med. 2020 Mar;45(3):187-194. doi: 10.1097/RLU.0000000000002921. Clin Nucl Med. 2020. PMID: 31977479

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

385 results

Results by year